tiprankstipranks
Lexicon Pharmaceuticals Announces Executive Leadership Changes
Company Announcements

Lexicon Pharmaceuticals Announces Executive Leadership Changes

Don't Miss our Black Friday Offers:

Lexicon Pharmaceuticals ( (LXRX) ) has shared an announcement.

Jeffrey L. Wade, the president and chief operating officer of the company, will be leaving his position on September 30, 2024. He will receive a year’s salary continuation, a substantial lump sum, and COBRA payments for health benefits, along with executive outplacement services. Additionally, he’s signed a consulting agreement for eight months post-termination at a monthly fee. Following Wade’s departure, Kristen L. Alexander, with extensive experience in finance and accounting, will step in as the principal financial officer.

For an in-depth examination of LXRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyLexicon price target lowered to $4 from $6 at H.C. Wainwright
TheFlyLexicon to eliminate commercial organization, focus on clinical development
TipRanks Auto-Generated NewsdeskLexicon Pharmaceuticals Appoints Ivan Cheung to Board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App